Novo Nordisk announced Q3 revenue of DKK 75.0 billion (USD 11.3 billion) representing 11% growth at constant exchange rates (CER), with the 9-month total reaching DKK 230.0 billion (USD 34.6 billion) driven by semaglutide portfolio sales of DKK 169.3 billion (USD 25.5 billion). The GLP-1R agonist franchise includes antidiabetic injection Ozempic generating DKK 95.3 billion (USD 14.3 billion), Rybelsus oral tablet contributing DKK 16.8 billion (USD 2.5 billion) and Wegovy injection for obesity achieving DKK 57.2 billion (USD 8.6 billion) with 54% growth year-on-year. US market sales reached DKK 128.4 billion (USD 19.3 billion), while China contributed DKK 14.9 billion (USD 2.2 billion) with 8% expansion.

Semaglutide maintains the leading position among global pharmaceutical products, exceeding the USD 23.3 billion sales for pembrolizumab and USD 24.8 billion for tirzepatide through the first three quarters. This year's US MASH indication approval for for Wegovy provides an additional growth driver alongside established diabetes and obesity indications. Novo's diabetes and obesity care division generated DKK 215.7 billion (USD 32.4 billion) representing 15% growth, with GLP-1 therapies contributing DKK 174.6 billion (USD 26.3 billion) and insulin products DKK 39.7 billion (USD 6.0 billion). The company updated its full-year guidance projecting 8% to 11% revenue growth at CER.

According to PharmCube's NextBiopharm® database, Wegovy has enjoyed constant sales growth since its 2022 launch. Click here to request a free trial for NextBiopharm®.